Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02480101
Other study ID # LAIV-H7N9-01
Secondary ID
Status Completed
Phase Phase 1
First received June 16, 2015
Last updated June 19, 2015
Start date October 2014
Est. completion date April 2015

Study information

Verified date June 2015
Source Research Institute of Influenza, Russia
Contact n/a
Is FDA regulated No
Health authority Switzerland: EthikkommissionRussia: Ethics Committee
Study type Interventional

Clinical Trial Summary

This is a single centre phase I, double-blind placebo-controlled study to assess reactogenicity, safety and immunogenicity of a live monovalent A/17/Anhui/2013/61 (H7N9) influenza vaccine in healthy male and female adults, 18 through 49 years of age .


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date April 2015
Est. primary completion date December 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 49 Years
Eligibility Inclusion Criteria:

- Legal male or female adult 18 through 49 years of age at the enrollment visit.

- Literate and willing to provide written informed consent.

- A signed informed consent.

- Free of obvious health problems, as established by the medical history and screening evaluations, including physical examination.

- Capable and willing to complete diary cards and willing to return for all follow-up visits

- Willing to comply with the rules of the isolation unit (including willing and able to take oseltamivir influenza antiviral medication, should that be recommended by a study physician).

- For females, willing to take reliable birth control measures through day 56.

Exclusion Criteria:

- Participation in another clinical trial involving any therapy within the previous three months or planned enrollment in such a trial during the period of this study.

- Receipt of any non-study vaccine within four weeks prior to enrollment or refusal to postpone receipt of such vaccines until four weeks after study completion.

- Practice of nasal irrigation on a regular basis within the past six months or has engaged in nasal irrigation within two weeks prior to enrollment.

- Recent history of frequent nose bleeds (more than 5 within the past year).

- Clinically relevant abnormal paranasal anatomy.

- Recent history (within the past month) of rhino or sinus surgery, or surgery for any traumatic injury of the nose.

- Current or recent (within two weeks of enrollment) acute respiratory illness with or without fever.

- Other acute illness at the time of study enrollment.

- Receipt of immune globulin or other blood products within three months prior to study enrollment or planned receipt of such products during the period of subject participation in the study.

- Chronic administration (defined as more than 14 consecutively-prescribed days) of immunosuppressants or other immune-modulating therapy within six months prior to study enrollment (for corticosteroids, this means prednisone or equivalent, 0.5 mg per kg per day; topical steroids are allowed, exclusive of nasal.)

- Participation in any previous trial of any H7 or H5 containing influenza vaccine.

- History of bronchial asthma.

- Hypersensitivity and allergy reactions after previous administration of any vaccine.

- History of wheezing after past receipt of any live influenza vaccine.

- Other AE following immunization (body temperature more than 40°C, collapse, non-febrile seizures, anaphylaxis), at least possibly related to previous receipt of any vaccine (not only influenza).

- Suspected or known hypersensitivity to any of the study vaccine components, including chicken or egg protein.

- Seasonal (autumnal) hypersensitivity to the natural environment.

- Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, metabolic, neurologic, psychiatric or renal functional abnormality, as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives. Subjects with physical examination findings or clinical laboratory screening results which would be graded 2 or higher on the AE severity grading scale will be excluded from entry into the study and will be excluded from receipt of dose two of study vaccine or placebo.

- History of leukemia or any other blood or solid organ cancer.

- History of thrombocytopenic purpura or known bleeding disorder.

- History of seizures.

- Known or suspected immunosuppressive or immunodeficient condition of any kind, including HIV infection.

- Known chronic HBV or HCV infection.

- Known tuberculosis infection or evidence of previous tuberculosis exposure.

- History of chronic alcohol abuse and/or illegal drug use.

- Claustrophobia or sociophobia.

- Pregnancy or lactation (a negative pregnancy test will be required before administration of study vaccine or placebo for all women of childbearing potential).

- Any condition that, in the opinion of the investigator, would increase the health risk to the subject if he/she participates in the study or would interfere with the evaluation of the study objectives.

- Allergic, including anaphylactic, reactions to the introduction of any vaccines in the subject's medical history (not only flu vaccine).

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
H7N9 live influenza vaccine
H7N9 live influenza vaccine
Placebo
Lyophilized purified allantoic fluid of chicken embryos with stabilizers

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Research Institute of Influenza, Russia Institute of Experimental Medicine, Russia, World Health Organization

Outcome

Type Measure Description Time frame Safety issue
Other Cellular immune responses (cytokine and T-cell) Cellular immune responses (cytokine and T-cell) was measured using isolated peripheral blood mononuclear cells (PBMCs) tested by flow cytometry and/or enzyme-linked immunosorbent spot (ELISPOT) assay. Days 0, 28 and 56 No
Primary Immediate reactions Immediate reactions occurring within two hours of administration of any dose, measured as observed by study staff or reported by the subject to study staff 2 hours Yes
Primary Solicited adverse events Adverse events commonly associated with intranasal vaccination (solicited local and systemic reactions), measured as observed by study staff or reported by the subject to study staff Greater than two hours after administration of any dose of study vaccine or placebo through 6 days following any dose Yes
Primary Changes from baseline in laboratory findings Abnormal laboratory findings from blood and urine specimens Days 3, 6 and 34 Yes
Primary Serious adverse events (SAEs) All SAEs during 56 days, as observed by study staff, reported by the subject to study staff, or noted by the subject on a diary card, including abnormal laboratory findings from blood specimens collected on Days 28 (pre-vaccination) and 56 4 weeks of receipt of any dose Yes
Secondary Immune responses Immune responses was parameterized as the proportion of subjects with at least a four-fold rise after each dose from baseline or as the mean titer after each dose in any of the following:
Serum hemagglutination inhibition (HAI) antibodies
Serum neutralizing antibodies
Serum immunoglobulin class A (IgA) or immunoglobulin class G (IgG) antibodies measured by enzyme-linked immunosorbent assay (ELISA)
Secretory IgA antibodies from the nasal mucosa detected in nasal wick specimens using ELISA
Secretory IgA antibodies in saliva specimens using ELISA
Days 0, 28 and 56 No
Secondary Virus shedding Virus shedding with virus detected by real-time reverse transcriptase polymerase chain reaction rRTPCR in nasal swabs at any time point (at day of vaccination and daily during hospitalization). Days 0-6 after each dose Yes
Secondary Virus stability Virus stability (virus detected and sequenced after inoculation into chicken eggs) Days 0-6 after each dose Yes
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A